Play

  1      0


Lidocaine Infusions for Chronic Pain



Credits: None available.

Outcomes

As a result of participating in this activity, learners will be better able to:

  • Continue with lidocaine infusions 
  • Begin using IV Lidocaine as an option for neuropathic pain
  • Use the guidelines discussed 
  • Make appropriate patient referral for IV lidocaine
  • Identify and manage the symptoms of lidocaine toxicity
  • Make changes to clinical operations 


Outline

  • History of Lidocaine Infusions
  • Evidence Review
    • Patient Selection
    • Indications
    • Contraindications
  • Real-world experience
  • Considerations for starting a lidocaine program
    • Protocols
    • Logistics
    • Lessons learned

Accreditation & Designation

Release date: This activity was released 8/19/2022.

Termination date: The content of this activity remains eligible for CME Credit until 8/18/2025, unless reviewed or amended prior to this date.

Claiming Credit: Watch the entire presentation and complete the Improvement Plan/Evaluation.


This activity includes discussions of unlabeled or investigational uses of commercial and/or developmental products.

This activity includes discussions and explorations of new and evolving topics. Such inclusion includes adequate justifications of statements based upon current science, evidence and clinical reasoning.


Neurovations Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Neurovations Education designates this other activity (blended learning) for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

California Required CME on Pain Management and the Appropriate Treatment of the Terminally Ill
AB487 requires physicians licensed in California to complete a one-time CME activity for 12 hours of credits that addresses both pain management and the appropriate care and treatment of the terminally ill. This activity contributes to achievement of requirements with AB487.


Disclosure of Financial Relationships & Measures to Resolve of Conflicts of Interest

[Presenter] Jill Sindt discloses the following financial relationships within the past 24 months: Consulting: Medtronic

No other person with control of, or responsibility for, the planning, delivery, or evaluation of accredited continuing education has, or has had within the past 24 months, financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships have been mitigated. Materials were reviewed in advance of the activity by person(s) that do not have conflicts of interest related to the content. In some cases, content may have been modified as part of the review and mitigation process. All clinical recommendations are evidence-based and free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines).


Additional Reading

  • Iacob, E., Hagn, E. E., Sindt, J., Brogan, S., Tadler, S. C., Kennington, K. S., ... & Junkins, S. R. (2018). Tertiary care clinical experience with intravenous lidocaine infusions for the treatment of chronic pain. Pain Medicine, 19(6), 1245-1253.
  • Hutson, P., Backonja, M., & Knurr, H. (2015). Intravenous lidocaine for neuropathic pain: a retrospective analysis of tolerability and efficacy. Pain medicine, 16(3), 531-536.
  • Kim, Y. C., Castañeda, A. M., Lee, C. S., Jin, H. S., Park, K. S., & Moon, J. Y. (2018). Efficacy and safety of lidocaine infusion treatment for neuropathic pain: a randomized, double-blind, and placebo-controlled study. Regional Anesthesia & Pain Medicine, 43(4), 415-424.
  • Schwenk, E. S., Walter, A., Torjman, M. C., Mukhtar, S., Patel, H. T., Nardone, B., ... & Silberstein, S. D. (2022). Lidocaine infusions for refractory chronic migraine: a retrospective analysis. Regional Anesthesia & Pain Medicine, 47(7), 408-413.
  • Mao J, Chen LL. Systemic lidocaine for neuropathic pain relief. Pain. 2000;87(1):7-17.
  • Kosharskyy B, Almonte W, Shaparin N, Pappagallo M, Smith H. Intravenous infusions in chronic pain management. Pain physician. 2013;16(3):231-249.



Speaker(s):

Category:

CME


Accreditation & Designation

Release date: This activity was released 8/19/2022.

Termination date: The content of this activity remains eligible for CME Credit until 8/18/2025, unless reviewed or amended prior to this date.

Claiming Credit: Watch the entire presentation and complete the Improvement Plan/Evaluation.


This activity includes discussions of unlabeled or investigational uses of commercial and/or developmental products.

This activity includes discussions and explorations of new and evolving topics. Such inclusion includes adequate justifications of statements based upon current science, evidence and clinical reasoning.


Neurovations Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Neurovations Education designates this other activity (blended learning) for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

California Required CME on Pain Management and the Appropriate Treatment of the Terminally Ill
AB487 requires physicians licensed in California to complete a one-time CME activity for 12 hours of credits that addresses both pain management and the appropriate care and treatment of the terminally ill. This activity contributes to achievement of requirements with AB487.


Disclosure of Financial Relationships & Measures to Resolve of Conflicts of Interest

[Presenter] Jill Sindt discloses the following financial relationships within the past 24 months: Consulting: Medtronic

No other person with control of, or responsibility for, the planning, delivery, or evaluation of accredited continuing education has, or has had within the past 24 months, financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships have been mitigated. Materials were reviewed in advance of the activity by person(s) that do not have conflicts of interest related to the content. In some cases, content may have been modified as part of the review and mitigation process. All clinical recommendations are evidence-based and free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines).

Credits

  • 0.75 - Physician
  • 0.75 - Non-Physician

You must be logged in and own this session in order to post comments.